• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Radical cystectomy vs. chemoradiation for the treatment of T2-4a N0 M0 bladder cancer].

作者信息

Klautke Gunther

机构信息

Klinikum Chemnitz gGmbH, Flemmingstraße 2, 09116, Chemnitz, Deutschland.

出版信息

Strahlenther Onkol. 2016 Nov;192(11):823-824. doi: 10.1007/s00066-016-1043-3.

DOI:10.1007/s00066-016-1043-3
PMID:27612469
Abstract
摘要

相似文献

1
[Radical cystectomy vs. chemoradiation for the treatment of T2-4a N0 M0 bladder cancer].[根治性膀胱切除术与放化疗治疗T2-4a N0 M0期膀胱癌的对比]
Strahlenther Onkol. 2016 Nov;192(11):823-824. doi: 10.1007/s00066-016-1043-3.
2
Sensitivity to chemoradiation predicts development of metastasis in muscle-invasive bladder cancer patients.对放化疗的敏感性可预测肌层浸润性膀胱癌患者发生转移的情况。
Urol Oncol. 2013 Oct;31(7):1270-5. doi: 10.1016/j.urolonc.2012.01.014. Epub 2012 Mar 2.
3
Radical cystectomy vs. chemoradiation in T2-4aN0M0 bladder cancer: a case-control study.T2-4aN0M0期膀胱癌根治性膀胱切除术与放化疗的病例对照研究
Urol Oncol. 2015 Jan;33(1):19.e1-19.e5. doi: 10.1016/j.urolonc.2014.09.014. Epub 2014 Nov 4.
4
Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.在保留膀胱的治疗方法中，接受诱导放化疗后疾病持续存在而行膀胱切除术的肌层浸润性膀胱癌患者，基于病理学的风险分层。
BJU Int. 2012 Sep;110(6 Pt B):E203-8. doi: 10.1111/j.1464-410X.2011.10874.x. Epub 2012 Jan 30.
5
Perioperative complications of radical cystectomy after induction chemoradiotherapy in bladder-sparing protocol against muscle-invasive bladder cancer: a single institutional retrospective comparative study with primary radical cystectomy.诱导放化疗后膀胱保留根治性膀胱切除术治疗肌层浸润性膀胱癌的围手术期并发症：与原发性根治性膀胱切除术的单机构回顾性对比研究。
Jpn J Clin Oncol. 2011 Dec;41(12):1373-9. doi: 10.1093/jjco/hyr150. Epub 2011 Oct 11.
6
Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients.选择保留膀胱方案，包括诱导低剂量放化疗联合根治性膀胱切除术加盆腔淋巴结清扫术治疗肌层浸润性膀胱癌：46 例初始患者的肿瘤学结局。
BJU Int. 2012 Mar;109(6):860-6. doi: 10.1111/j.1464-410X.2011.10425.x. Epub 2011 Aug 19.
7
Bladder preservation by combined modality therapy for invasive bladder cancer.联合治疗方式对浸润性膀胱癌的膀胱保留作用
J Clin Oncol. 1997 Mar;15(3):1022-9. doi: 10.1200/JCO.1997.15.3.1022.
8
Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer.挽救性膀胱切除术治疗肌层浸润性膀胱癌保膀胱治疗失败后的并发症和长期结果。
J Urol. 2012 Feb;187(2):463-8. doi: 10.1016/j.juro.2011.09.159. Epub 2011 Dec 15.
9
[Treatment of bladder cancer in the elderly].[老年膀胱癌的治疗]
Urologe A. 2015 Apr;54(4):510-5. doi: 10.1007/s00120-015-3777-4.
10
Outcomes of patients after aborted radical cystectomy for intraoperative findings of metastatic disease.
BJU Int. 2008 Dec;102(11):1539-43. doi: 10.1111/j.1464-410X.2008.07877.x. Epub 2008 Aug 22.

本文引用的文献

1
Radical cystectomy vs. chemoradiation in T2-4aN0M0 bladder cancer: a case-control study.T2-4aN0M0期膀胱癌根治性膀胱切除术与放化疗的病例对照研究
Urol Oncol. 2015 Jan;33(1):19.e1-19.e5. doi: 10.1016/j.urolonc.2014.09.014. Epub 2014 Nov 4.
2
Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.选择性膀胱保留联合治疗后肌层浸润性膀胱癌患者的长期预后：放射肿瘤学组8802、8903、9506、9706、9906和0233方案的汇总分析
J Clin Oncol. 2014 Dec 1;32(34):3801-9. doi: 10.1200/JCO.2014.57.5548. Epub 2014 Nov 3.
3
Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up.
膀胱癌：欧洲肿瘤内科学会诊断、治疗及随访实践指南
Ann Oncol. 2014 Sep;25 Suppl 3:iii40-8. doi: 10.1093/annonc/mdu223. Epub 2014 Aug 5.
4
Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.经尿道手术联合每日两次放疗加紫杉醇-顺铂或氟尿嘧啶-顺铂治疗伴选择性膀胱保留和辅助化疗的肌层浸润性膀胱癌患者（RTOG 0233）：一项随机多中心 2 期试验。
Lancet Oncol. 2013 Aug;14(9):863-72. doi: 10.1016/S1470-2045(13)70255-9. Epub 2013 Jul 1.
5
15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment.膀胱癌经尿道切除术后联合放化疗或放疗的 15 年生存率。
Anticancer Res. 2011 Mar;31(3):985-90.
6
Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia.高危 T1 和 T2 膀胱癌的四模态治疗：经尿道肿瘤切除术联合同期放化疗和区域性深部热疗。
Radiother Oncol. 2009 Nov;93(2):358-63. doi: 10.1016/j.radonc.2009.09.018.
7
Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer.膀胱癌患者经尿道手术后采用顺铂和5-氟尿嘧啶进行放化疗。
Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1072-80. doi: 10.1016/j.ijrobp.2007.01.054. Epub 2007 Apr 30.